ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Present at Upcoming Investor Conference

06 يونيو 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يونيو 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Leadership Transition

24 مايو 2023 17:00:03 بحسب Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

09 مايو 2023 16:02:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مايو 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

02 مايو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

28 أبريل 2023 16:01:57 بحسب Nasdaq GlobeNewswire

Arcutis to Report First Quarter Financial Results

25 أبريل 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

18 أبريل 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

12 أبريل 2023 16:45:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 أبريل 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

05 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

18 مارس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

09 مارس 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 مارس 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 فبراير 2023 16:02:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

21 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

08 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 فبراير 2023 16:09:57 بحسب Nasdaq GlobeNewswire

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

14 يناير 2023 04:00:00 بحسب Nasdaq GlobeNewswire